Helixmith Co., Ltd.
Quick facts
Phase 3 pipeline
- Engensis · Other
- Engensis (VM202) · Cardiovascular; Regenerative Medicine
VM202 is a plasmid DNA therapeutic that encodes hepatocyte growth factor (HGF) to promote angiogenesis and tissue repair in ischemic tissues.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Helixmith Co., Ltd.
What is Helixmith Co., Ltd.'s pipeline?
Helixmith Co., Ltd. has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Engensis, Engensis (VM202).
Related
- Sector hub: All tracked pharma companies